---
schema_version: "secwatch.filing_event.v1"
accession: "0001689375-25-000049"
form_type: "8-K"
ticker: "TRDA"
cik: "0001689375"
company_name: "Entrada Therapeutics, Inc."
filed_at: "2025-11-06T23:59:59+00:00"
generated_at: "2026-05-16T23:47:28.921061+00:00"
event_type: "earnings"
sentiment: "negative"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Entrada Q3 net loss widens to $44.1M; DMD pipeline on track for data in 2026

## Summary
- Net loss of $44.1M for Q3 2025, compared to $14.0M net loss in Q3 2024; collaboration revenue fell to $1.6M from $19.6M.
- Cash, cash equivalents & marketable securities of $326.8M extended runway into Q3 2027.
- ELEVATE-44-201 cohort 1 data on track for Q2 2026; first patient dosed in ELEVATE-45-201 with cohort 1 data expected mid-2026.
- Filed UK regulatory authorization for ENTR-601-50; plans to submit EU applications in H2 2026.
- Vertex VX-670 (DM1) trial enrollment and dosing on track for completion in H1 2026.

## SEC filing metadata
- accession: 0001689375-25-000049
- form_type: 8-K
- ticker: TRDA
- cik: 0001689375
- company_name: Entrada Therapeutics, Inc.
- filed_at: 2025-11-06T23:59:59+00:00
- event_type: earnings
- sentiment: negative
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1689375/000168937525000049/0001689375-25-000049-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1689375/000168937525000049/trda-20251106.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001689375-25-000049
- JSON: https://secwatch.observer/filing/0001689375-25-000049.json
- Plain text: https://secwatch.observer/filing/0001689375-25-000049.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.